Biocompatibility is straightforward at its core: your device materials must not cause an unacceptable biological response in the body under their intended use conditions. In practice, that means you need to understand how your device contacts the body, for how long, what biological hazards exist, and how you'll demonstrate that biological risks are acceptable. What FDA Biocompatibility Requirements Actually Cover FDA uses biocompatibility evaluation to judge whether your devi

On April 23, 2026, the Centers for Medicare & Medicaid Services (CMS) and the FDA announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, a groundbreaking initiative designed to accelerate Medicare beneficiary access to FDA-designated Breakthrough Devices. Combined with the expanding Total Product Life Cycle Advisory Program (TAP), these programs fundamentally change how manufacturers should approach development strategy, evidence gen

Contract research organizations occupy a unique position in the medical device ecosystem. While CROs don't typically hold FDA establishment registrations as manufacturers, the quality of services they provide directly impacts their clients' QMSR compliance, biocompatibility evaluations, and regulatory submissions. The QMSR's emphasis on process-based quality management, expanded FDA inspection authority, and integration of biocompatibility with design controls creates both ch

ISO 10993-1 sits at the center of how regulators expect you to think about biological safety. It is the international standard for biological evaluation of medical devices, and Part 1 provides the framework for structuring your entire biocompatibility strategy within a risk management process. The 2025 edition, represents the most significant change to biocompatibility evaluation in decades. The familiar endpoint matrix that guided testing decisions for over 30 years has been